



THE LAW OFFICE OF
STEPHEN JOSEPH LASKERO
A California Law office
3451 Via Montebello, Suite 192-409
Carlsbad, CA 92009
stephenlaw7@ymail.com
760-452-6778

OTC Markets Group Inc.
300 Vesey Street, 12th Floor,
New York, NY 10282,
issuers@otcmarkets.com

June 8, 2021

Re: Attorney Letter for Caduceus Software Systems Corp. (CSOC) Regarding Current Public Information

Dear Sir or Madam:

The purpose of this correspondence is to inform OTC Markets and the public of the availability of current public information for the “Issuer” Caduceus Software Systems Corp. (CSOC) a Wyoming based holding company. This law firm has been retained by the Issuer for the sole purpose of authoring a reasoned opinion regarding the availability of current public information as that term is defined in Rule 144(c) (2) of the Securities Act of 1933 as amended. The OTC Markets Group is entitled to rely on this opinion and may publish this letter through the OTC Market Disclosure and News Service (otcmarkets.com) for the purpose of making this information available to the public.

The undersigned and sole author of this correspondence is licensed to practice law in the state of California, the Southern Dist. of California, and the United States Supreme Court. The Undersigned is also a United States resident and is entitled to practice before the United States Securities and Exchange Commission (the “SEC”) and has not been disciplined or otherwise prohibited from that practice. The undersigned is not currently and never has been subject to an investigation, hearing, or proceeding by the SEC, the U.S. Commodity Futures Trading Commission, the Financial Industry Regulatory Authority, or any other federal, state, or foreign entity. Moreover, the undersigned never has been and is not currently suspended or barred from practice in any foreign or domestic court of law or other tribunal or been charged in a civil or criminal case. Finally, the undersigned does not beneficially own any of the issuer’s stock and has not been promised any stock in the future for any reason whatsoever.

Limitations, Assumptions and Facts

In support of this opinion, the undersigned has reviewed applicable federal laws, rules and regulations including specifically the Securities Act of 1933 as amended and other relevant laws deemed necessary to render this opinion. The undersigned has also reviewed the corporate records determined to be appropriate, verified or assumed the legal capacity of all persons and entities, the genuineness of all signatures, the authenticity of all documents, and the veracity of all individuals who provided information regarding this matter.

In the portion of this letter that relies upon the information and documentation contained in the OTC disclosures of the issuer, the undersigned has not made, nor will he make any independent investigation regarding the representations contained therein. However, during my review of the documentation and conversations with the issuer's representatives, I did not reach the conclusion that any of the information I received was incorrect or disingenuous. Therefore, the information relied upon is believed to be true and reliable, and the documents genuine. This opinion is based solely on the facts, limitations and assumptions described in this letter and is not intended to be expanded to any other situation not discussed herein.

In the formation of the opinions contained in this letter, the undersigned has examined the following specific documents available by publication through the OTC Disclosure and News service:

<u>Publish Date</u>	<u>Title</u>	
06/07/2021	<u>Annual Report - Amended CSOC Annual Report for the Fiscal Year ended March 31, 2021</u>	03/31/2021
05/19/2021	<u>Quarterly Report - CSOC Quarterly Report - December 31 2020</u>	12/31/2020
05/19/2021	<u>Quarterly Report - CSOC Quarterly Report - September 30, 2020</u>	09/30/2020
05/19/2021	<u>Quarterly Report - CSOC Quarterly Report - June 30, 2020</u>	06/30/2020
05/19/2021	<u>Annual Report - CSOC Annual Report for the Fiscal Year ended March 31, 2020</u>	03/31/2020
05/19/2021	<u>Quarterly Report - CSOC Quarterly Report - December 31 2019</u>	12/31/2019
05/19/2021	<u>Quarterly Report - CSOC Quarterly Report - September 30, 2019</u>	09/30/2019

The undersigned also reviewed the Pink Basic Disclosure Guidelines for the fiscal year ending March 31, 2020, and fiscal year ending March 31, 2021.

The undersigned has met with Alex Chen, the Chief Executive Officer, financial officer, and sole Director of Caduceus Software Systems Corp via telephone conference on at least three separate

occasions, May 25, June 3, and June 7, 2021. During these conversations, the information published by the issuer was discussed and confirmed. The undersigned has also met via telephone conference with Rachel Boulds, the Certified Public Accountant responsible for the financial information contained in the above referenced OTC disclosures filed on May 19, 2021, other than the annual report for the period ending March 31, 2021. This report was filed June 7, 2021 by Alex Chen, CEO and CFO of the company who has adequate knowledge and understanding to file the report as described below. These conversations took place on June 7, 2021.

The financial statements contained in the Information for the fiscal year ending March 31, 2020, and the quarterly reports for September 30, 2019, December 31, 2019, June 30, 2020, September 30, 2020 and December 31, 2020, are unaudited financial statements prepared by Rachel Boulds, a Certified Public Accountant, who has identified herself as a service provider for the Company. Ms. Boulds is located at 6371 S. Glenoaks Street in Murray Utah. During our discussions, Ms. Boulds confirmed that she is a Certified Public Accountant, licensed in Utah with twenty years of public accounting experience, and that she completed the above referenced documents as described. The undersigned is informed and believes that Ms. Boulds has no other affiliation with the company.

The annual report for the fiscal year ending March 31, 2021, was completed by Alex Chen, the CEO and chief financial officer of the company. He is familiar with the company's financials and has a bachelor's degree in accounting, worked for Certified Public Accounting firms and was a CPA in Australia. He also served as a CFO for an Amex traded company, and holds series 79, 7 and 63 designations.

After discussing this matter with the CEO, Alexander Chen, on June 7, 2021, the undersigned has received written confirmation that none of the individuals identified as owning 5% or more of the company's common stock are currently under investigation by any federal or state agency for the violation of any securities laws, and never have been charged, indicted or been found guilty of any securities law violations including legal counsel. Consequently, to the best of my knowledge, after reasonable inquiry, the above referenced information can be relied upon by OTC Markets as being true.

The undersigned confirmed the number of outstanding shares of the Issuer by reviewing the information contained in the yearend financial statements, contacting the transfer agent, Securities Transfer Corp., and reviewing the CSOC "Security Details" available on the OTC Disclosure and News Service, as of June 7, 2021.

Non-Shell Status

According to the issuer's OTC disclosures it is not now and never has been a "shell company" as defined by Rule 405 of the Securities Act of 1933 and 12b-2 of the Exchange Act of 1934. My factual inquiries support the conclusion that the company has been an ongoing concern with more than nominal assets and operations since its inception based on its OTC disclosures and my discussions with management.

Legal Opinion

It is the undersigns opinion that the information provided by the issuer presents “adequate current public information” regarding the issuer and its securities that is available to the public as those terms are defined in Rule 144(c)(2) of the Securities Act of 1933. The available information contains all the information a broker-dealer would need to publish a quote for the Securities under Rule 15c2-11 of the Securities Exchange Act of 1934, as amended. It also is consistent with OTC Markets Group’s Pink Basic Disclosure Guidelines that have been published through the OTC Disclosure & News Service.

The opinions contained in this letter are limited to the laws of the United States and the state of California, as well as the facts and circumstances described herein. Nothing in this correspondence should be construed as a guarantee or a definitive opinion of fact. All opinions assume that the presented documents and statements of management are true, and the facts delineated in the documents reviewed in support of this opinion are genuine. The letter is being presented in accordance with the guidelines of the OTC Market Disclosure and New Service and OTC is hereby granted complete permission and rights to publish this letter. This correspondence applies only to law, facts and circumstances described herein and should not be relied upon by any other person or entity for any purpose. No other publication, use or reproduction of this correspondence is authorized without the specific written permission of the undersigned.

Regards,



Stephen Laskero
Attorney at Law